Ticker
ACXP

Price
3.04
Stock movement up
+0.12 (4.11%)
Company name
Acurx Pharmaceuticals LLC
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
31.20M
Ent value
20.75M
Price/Sales
-
Price/Book
2.92
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-37.83%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-11-29

DIVIDENDS

ACXP does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.92
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count10.26M
EPS (TTM)-214748.36
FCF per share (TTM)-1.26

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-14.01M
Net income (TTM)-2670.15B
EPS (TTM)-214.75K
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash11.08M
Net receivables0.00
Total current assets11.32M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets11.32M
Accounts payable633.03K
Short/Current long term debt0.00
Total current liabilities633.03K
Total liabilities633.03K
Shareholder's equity10.69M
Net tangible assets10.69M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-8.79M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-8.79M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-214748.36%
Return on Assets-214748.36%
Return on Invested Capital-214748.36%
Cash Return on Invested Capital-82.26%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.90
Daily high3.14
Daily low2.90
Daily Volume26K
All-time high7.89
1y analyst estimate12.00
Beta-
EPS (TTM)-214748.36
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ACXPS&P500
Current price drop from All-time high-61.47%-17.12%
Highest price drop-69.33%-56.47%
Date of highest drop24 May 20229 Mar 2009
Avg drop from high-48.06%-11.46%
Avg time to new high361 days13 days
Max time to new high360 days1805 days
COMPANY DETAILS
ACXP (Acurx Pharmaceuticals LLC) company logo
Marketcap
31.20M
Marketcap category
Small-cap
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Employees
3
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ann...
November 14, 2022
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
November 13, 2022
New to The Street / Newsmax TV Announces Episode #403, Eight Interviews, Airing November 6, 2022, 10-11 AM ET 403rd TV episode features the following: 1). Mikra Cellular Sciences (a division of Lifeis...
November 4, 2022
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ann...
November 1, 2022
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, tod...
October 26, 2022
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, tod...
October 17, 2022
New to The Street Interviews Five Corporate Guest, Episode #394 to Air on The Fox Business Network, Tonight October 10, 2022, at 10:30 PM PT New to The Street's 394th televised episode:1). CDL 1000 2)...
October 10, 2022
New to The Street / Newsmax Announces Nine Guest Interviews on This Week's Televised Broadcast New to The Street's 393rd episode features the followings: 1). Fintech/Cryptocurrency - interview with Fa...
October 7, 2022
New to The Street TV Announces Corporate Interviews on its 390th Show, Airing on the Fox Business Network, Tonight, Monday, September 26, 2022, at 10:30 PM PT New to The Street’s TV episode features t...
September 26, 2022
New to The Street TV Announces its Business Guest Interviews, Episode #388 Airs on Bloomberg TV New to The Street’s TV episode air the following business interviews: 1). PetVivo Holdings, Inc. (NASDAQ...
September 23, 2022
Next page